Novartis AG
137.48USD
-0.2200 (-0.16%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 43.5B | 46.7B | 51.7B | 56.7B | 57.6B | 61.3B |
| Q1 | — | — | — | — | 13.5B | — |
| Q2 | — | — | — | 14.8B | 15.0B | — |
| Q3 | — | — | — | 14.4B | 14.6B | — |
| Q4 | — | — | — | 13.9B | 14.9B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 3.17 | 7.10 | 5.87 | 7.15 | 8.80 | 9.81 |
| Q1 | — | — | — | — | 1.65 | — |
| Q2 | — | — | — | 2.06 | 1.71 | — |
| Q3 | — | — | — | 2.02 | 2.23 | — |
| Q4 | — | — |
Fiscal period: Reported, Estimated. Reported figures: Yahoo Finance (limited history). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| — |
| 1.25 |
| 2.10 |
| — |